The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
The inspection concluded with zero form 483 observations
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Encouraging early detection and breaking the silence around men’s health
Subscribe To Our Newsletter & Stay Updated